文献速递乳腺癌放疗放疗物理与技术

MonoHER通过稳定p53选择性增强p53野生型乳腺癌的放疗反应

MonoHER selectively enhances the radiotherapy response in p53 wild-type breast cancer via stabilization of p53.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-03-15

该体外研究评估了黄酮衍生物MonoHER在乳腺癌细胞和正常乳腺细胞中的放疗增敏作用。结果显示MonoHER选择性增强p53野生型MCF7细胞的辐射诱导细胞静止效应并增加凋亡和DNA损伤,伴随ATM/p53信号上调,而对正常MCF10A细胞有保护作用,提示其作为放疗增敏佐剂的潜力。

要点

  • MonoHER选择性增强p53野生型乳腺癌细胞的辐射反应。
  • MonoHER对正常乳腺细胞有保护作用。
  • MonoHER通过稳定和激活p53发挥增敏作用。

核心结论

  • MonoHER仅对p53功能完整的乳腺癌细胞产生适度的放疗增敏作用,机制为稳定并激活p53。

研究设计与样本

  • 体外研究,使用不同p53状态的乳腺癌细胞(MCF7野生型、T47D突变型)和正常乳腺细胞(MCF10A),予以MonoHER和辐射处理。

主要发现

  • MonoHER选择性增强MCF7(p<0.01)和T47D(p<0.05)的辐射诱导细胞静止效应,但对MCF10A有保护作用(p<0.01)。
  • 联合处理增加MCF7细胞凋亡(p<0.001)和DNA损伤(p=0.045),并上调p-ATM(p=0.011)、p-p53(p=0.023)和总p53(p=026),而T47D和MCF10A中无显著差异。
  • 分子对接和CETSA证实MonoHER与野生型p53直接结合,增加其热稳定性。
  • MonoHER单药细胞毒性极小,提示其作用为 priming 而非直接杀伤。

临床怎么用

  • 提示MonoHER可能作为p53野生型乳腺癌的放疗增敏佐剂,但需进一步体内和临床研究验证。

局限性

  • 研究仅为体外实验,样本量有限,未涉及体内模型或临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiotherapy is one of the standard treatments for breast cancer, but its efficacy is limited by tumour radioresistance. Radiosensitizers can improve treatment outcomes. MonoHER, a flavonoid derivative, has shown anticancer potential; however, its role in radiosensitization has not been investigated. Here, we determined the radiosensitizing properties of monoHER in vitro in breast cancer and normal mammary cells. METHODS: Breast cancer cells with different p53 status (MCF7, wild-type; T47D, mutant) and normal mammary cells (MCF10A) were treated with monoHER and radiation. Cell viability, clonogenic survival, apoptosis, and γ-H2AX foci were assessed. Western blotting examined ATM/p53 signalling. Interaction of monoHER with p53 was analysed by molecular docking and CETSA. RESULTS: MonoHER selectively enhanced radiation-induced cytostatic effects in MCF7 (p < 0.01) cells and in T47D (p < 0.05), but had protective effect in MCF10A (p < 0.01) cells. Combined treatment increased apoptosis (p < 0.001) and DNA damage (p = 0.045) in MCF7 cells, accompanied by upregulation of p-ATM (p = 0.011), p-p53 (p = 0.023), and total p53 (p = 026), while in T47D and MCF10A cells, there is no significant difference. Docking and CETSA confirmed direct binding of monoHER to wild-type p53, increasing its thermal stability. MonoHER alone showed minimal cytotoxicity, suggesting a priming rather than direct killing effect. CONCLUSION: MonoHER modestly sensitize only p53-proficient breast cancer cells to radiation by stabilizing and activating p53, highlighting its potential as an adjuvant radiosensitizer.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Li C, Li X, Biemans R, et al. MonoHER selectively enhances the radiotherapy response in p53 wild-type breast cancer via stabilization of p53. Clin Transl Radiat Oncol. 2026. PMID: 41884186. doi:10.1016/j.ctro.2026.101147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。